Results of the double-blind, placebo-controlled trial expected in Q1 2021 Preparations for rolling Marketing Authorization Application in Europe commenced Trial results to confirm unique triple mode of action to prevent infection, organ injury and inflammation Press release (EN) | Presseaussendung (DE)

Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431 Inhibitors discovered at Domainex via virtual and fragment screening Press release (EN) | Presseaussendung (DE)

Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial First data on the effect of blocking the spike protein in COVID-19 patient confirm mode of action of APN01 specifically targeting SARS-CoV-2 Press release (EN) | Presseaussendung (DE)

APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials. Press release (EN) | Presseaussendung (DE)

APEIRON Biologics AG has successfully completed a financing round totaling EUR 17.5 million, thus securing the further development of its drug candidate APN01 for the treatment of seriously ill COVID-19 patients and the further development of immuno-oncology projects. Expansion of the ongoing phase II clinical trial to USA and Russia planned. Press release (EN) |...

Substantial financing measures through capital increase with subscription rights and private placement as well as grants Vienna Insurance Group is secured as lead investor of the financing round and secures the private placement Participation in capital increase by existing shareholders as well as new institutional and private investors confirmed Public grant funding committed Financing secures...

We are developing a potential drug candidate APN01, based on our proprietary ACE2 platform to address the growing global health threat. APN01 is ideally suited to prevent the infection with SARS-CoV-2, reduce injury to multiple organs and mitigate the deleterious consequences of established viral infection. APEIRON´s APN01 has a unique triple Mode of Action APN01...